1. Market Research
  2. > Pharmaceutical Market Trends
  3. > NeuroVive Pharmaceutical AB - Product Pipeline Review - 2015

NeuroVive Pharmaceutical AB - Product Pipeline Review - 2015

  • October 2015
  • -
  • Global Markets Direct
  • -
  • 33 pages

NeuroVive Pharmaceutical AB - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘NeuroVive Pharmaceutical AB - Product Pipeline Review - 2015’, provides an overview of the NeuroVive Pharmaceutical AB’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of NeuroVive Pharmaceutical AB’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of NeuroVive Pharmaceutical AB including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of NeuroVive Pharmaceutical AB’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the NeuroVive Pharmaceutical AB’s pipeline products

Reasons to buy

- Evaluate NeuroVive Pharmaceutical AB’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of NeuroVive Pharmaceutical AB in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the NeuroVive Pharmaceutical AB’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of NeuroVive Pharmaceutical AB and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of NeuroVive Pharmaceutical AB
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of NeuroVive Pharmaceutical AB and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

NeuroVive Pharmaceutical AB - Product Pipeline Review - 2015
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
NeuroVive Pharmaceutical AB Snapshot 5
NeuroVive Pharmaceutical AB Overview 5
Key Information 5
Key Facts 5
NeuroVive Pharmaceutical AB - Research and Development Overview 6
Key Therapeutic Areas 6
NeuroVive Pharmaceutical AB - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Out-Licensed Products 10
Out-Licensed Products/Combination Treatment Modalities 11
NeuroVive Pharmaceutical AB - Pipeline Products Glance 12
NeuroVive Pharmaceutical AB - Late Stage Pipeline Products 12
Phase III Products/Combination Treatment Modalities 12
NeuroVive Pharmaceutical AB - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
NeuroVive Pharmaceutical AB - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 15
NeuroVive Pharmaceutical AB - Drug Profiles 16
cyclosporine 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
NVP-014 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
NVP-019 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
NVP-015 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
NeuroVive Pharmaceutical AB - Pipeline Analysis 22
NeuroVive Pharmaceutical AB - Pipeline Products by Target 22
NeuroVive Pharmaceutical AB - Pipeline Products by Route of Administration 23
NeuroVive Pharmaceutical AB - Pipeline Products by Molecule Type 24
NeuroVive Pharmaceutical AB - Pipeline Products by Mechanism of Action 25
NeuroVive Pharmaceutical AB - Recent Pipeline Updates 26
NeuroVive Pharmaceutical AB - Dormant Projects 29
NeuroVive Pharmaceutical AB - Discontinued Pipeline Products 30
Discontinued Pipeline Product Profiles 30
cyclosporine 30
NeuroVive Pharmaceutical AB - Locations And Subsidiaries 31
Head Office 31
Other Locations and Subsidiaries 31
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 32
Disclaimer 33

List of Tables
NeuroVive Pharmaceutical AB, Key Information 5
NeuroVive Pharmaceutical AB, Key Facts 5
NeuroVive Pharmaceutical AB - Pipeline by Indication, 2015 7
NeuroVive Pharmaceutical AB - Pipeline by Stage of Development, 2015 8
NeuroVive Pharmaceutical AB - Monotherapy Products in Pipeline, 2015 9
NeuroVive Pharmaceutical AB - Out-Licensed Products in Pipeline, 2015 10
NeuroVive Pharmaceutical AB - Out-Licensed Products/ Combination Treatment Modalities, 2015 11
NeuroVive Pharmaceutical AB - Phase III, 2015 12
NeuroVive Pharmaceutical AB - Phase II, 2015 13
NeuroVive Pharmaceutical AB - Preclinical, 2015 14
NeuroVive Pharmaceutical AB - Discovery, 2015 15
NeuroVive Pharmaceutical AB - Pipeline by Target, 2015 22
NeuroVive Pharmaceutical AB - Pipeline by Route of Administration, 2015 23
NeuroVive Pharmaceutical AB - Pipeline by Molecule Type, 2015 24
NeuroVive Pharmaceutical AB - Pipeline Products by Mechanism of Action, 2015 25
NeuroVive Pharmaceutical AB - Recent Pipeline Updates, 2015 26
NeuroVive Pharmaceutical AB - Dormant Developmental Projects,2015 29
NeuroVive Pharmaceutical AB - Discontinued Pipeline Products, 2015 30
NeuroVive Pharmaceutical AB, Subsidiaries 31

List of Figures
NeuroVive Pharmaceutical AB - Pipeline by Top 10 Indication, 2015 7
NeuroVive Pharmaceutical AB - Pipeline by Stage of Development, 2015 8
NeuroVive Pharmaceutical AB - Monotherapy Products in Pipeline, 2015 9
NeuroVive Pharmaceutical AB - Pipeline by Top 10 Target, 2015 22
NeuroVive Pharmaceutical AB - Pipeline by Top 10 Route of Administration, 2015 23
NeuroVive Pharmaceutical AB - Pipeline by Top 10 Molecule Type, 2015 24
NeuroVive Pharmaceutical AB - Pipeline Products by Top 10 Mechanism of Action, 2015 25

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.